Showing papers in "Hepatology Research in 2020"

TL;DR: The incidence of liver injury, as assessed by serum analysis (AST, ALT, total Bilirubin and Albumin levels), seems to be higher in patients with severe COVID‐19 infection.

TL;DR: The Committee has decided to publish a new English version of the JSH guidelines, covering general information about treatment for hepatitis C, drugs used, recommended treatments for chronic hepatitis and cirrhosis, and special populations, such as patients who have renal impairment, are on dialysis, or have developed recurrence of hepatitis C after liver transplantation.

TL;DR: The results of the analysis show that the prognosis of HCC is improving dramatically and is expected that the data obtained from this nationwide follow‐up survey will contribute to advancing clinical research, including the design of clinical trials, as well as the treatment strategy of primary liver cancer in the clinical practice setting.

TL;DR: It is urgent to investigate liver function changes of COVID‐19 patients with chronic HBV infection, and how severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in turn affects the course of chronicHBV infection.

TL;DR: This 2019 version of the Guidelines for the Management of Hepatitis B includes updates to treatment recommendations and management of drug-resistant HBV that reflect the new availability of these drugs, and new information about HBV reactivation with each update.

TL;DR: This work elucidated the relationships among clinical profiles, biochemical response to UDCA and gut microbiome composition in patients with PBC.

TL;DR: Non‐alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD) and prevalence is rising in Asia due to increasing rates of urbanization, sedentary lifestyles, and poor nutrition.

TL;DR: This study compared the frequency of adverse events and prognosis between elderly and non‐elderly patients with HCC who received lenvatinib.

TL;DR: Lenvatinib was effective for patients who did not meet the REFLECT inclusion criteria, however, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion.

TL;DR: This work investigated whether fibrosis identified by hepatic stiffness measurements based on magnetic resonance elastography (MRE) affects attenuation coefficient measurement using UGAP for the evaluation of hepatic steatosis.

TL;DR: This work investigated and compared the changes in liver functional reserve during lenvatinib or sorafenib therapy in patients with advanced HCC.

TL;DR: Current knowledge about the role of gut microbiota in the pathogenesis of non‐alcoholic fatty liver disease and alcohol‐related liver disease, as well as the relevance of microbiota or bile acid‐based approaches in the management of those liver diseases are summarized.

TL;DR: The Enhanced Liver Fibrosis test comprises a logarithmic algorithm combining three serum markers of hepatic extracellular matrix metabolism to diagnose liver fibrosis and to compare it with that of liver stiffness measurement by FibroScan in non‐alcoholic fatty liver disease.

TL;DR: The effect of Sil on intestinal flora dysbiosis induced by a high‐fat diet (HFD) is examined to examine the effect of the naturally occurring hepatoprotective agent on gut microbiota.

TL;DR: The aim of this study was to confirm the diagnostic accuracy of FAST score of Japanese patients and compare the cut‐off values and diagnostic accuracy between the FibroScan M and XL probes.

TL;DR: The underlying mechanism of non‐obese non‐alcoholic fatty liver disease (NAFLD) has not been fully elucidated and patients with NAFLD are classified by sex and body mass index to clarify the background pathophysiology.

TL;DR: This work investigated the ability of attenuation imaging (ATI) to detect steatosis that was identified by proton density fat fraction on magnetic resonance imaging (MRI) in patients with chronic liver disease.

TL;DR: The aim of this study was to investigate the predictive factors of objective response rate (ORR) and progression‐free survival (PFS) and the correlation of albumin‐bilirubin (ALBI) grade with decreased appetite and fatigue in hepatocellular carcinoma patients treated with lenvatinib.

TL;DR: This work aimed to investigate the prevalence of advanced fibrosis in the general population and the profiles associated withAdvanced fibrosis using a data‐mining analysis.

TL;DR: The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology drafted the first version of the clinical practice guidelines for the management of hepatitis C virus (HCV) infection in 2012 and has been publishing updates as new drugs for hepatitis C become available and new indications for existing drugs are added.

TL;DR: This study aimed to determine the optimal psoas muscle mass index (PMI) cut‐off values for diagnosis of skeletal muscle mass loss.

TL;DR: This study aimed to investigate the radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma in real‐world practice.

TL;DR: This study aimed to determine the incidence of MSI‐H tumors in Japanese patients with advanced hepatocellular carcinoma (HCC) and Pembrolizumab.

TL;DR: There is increasing evidence that inflammation‐based prognostic scores are stage‐independent predictors of poor outcome in patients with hepatocellular carcinoma (HCC), but findings were observed in a small‐sized study comparing the prognostic value of these scores for patients after curative resection for HCC.

TL;DR: The aim of the study was to reveal the clinicopathological characteristics and prognostic factors of cHCC‐CCA after hepatic resection (HR) of combined hepatocellular cholangiocarcinoma.

TL;DR: Investigation of prognosis and characteristics of patients with HCC treated with TKI based on liver function and the extent of portal vein tumor thrombosis found some cases with Barcelona Clinic Liver Cancer stage C disease still had poor prognosis.

TL;DR: The incidence and clinical characteristics of FALD‐HCC, which can arise from Fontan‐associated liver disease (FALD), are examined.

TL;DR: The impact of three different criteria for evaluating radiological objective response (OR) on overall survival in real‐world data is investigated.

TL;DR: The aim of this single‐arm prospective study is to evaluate the efficacy of pemafibrate in NAFLD patients with DL.

TL;DR: This work investigated the possible biological performance of a novel liver‐specific long non‐coding RNA, LINC02499, in HCC.